Company: SCLXW
Filing Date: 2025-07-23
Form Type: 424B3
Source: 0001193125-25-163077
Chunk: 241

Company: Scilex Holding Co
Filing Date: 2025-07-23
Form: 424B3
Chunk 241
---
 written or
oral, which may have related to the subject matter hereof.

(e) . This Agreement may not be
amended or modified except by an instrument in writing signed by each Party to this Agreement. No provision of this Agreement may be waived except by a written instrument signed by the Party against whom the waiver is to be effective. No failure or
delay by any Party hereto in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right,
power or privilege.

11

(f) This Agreement may be terminated by Oramed (the
“”) by written notice to Scilex if Purchaser (I) fails to make any of the payments under any of , or
, or (II) has not exercised the Option by the applicable date set forth in in respect of the Initial Warrant Shares or Final Warrant Shares, (each such failure to pay
the Option Fee or Purchase Price (or applicable portion thereof that is due and owing) or to exercise the Option, a “”); , , that (i) the Termination Right must be exercised within
twenty (20) Business Days of such Termination Event and (ii) the terms and provisions of , , through
, and this shall survive any termination of this Agreement. Notwithstanding anything herein to the contrary, any termination pursuant to
this shall not be deemed to release any Party from any liability for fraud or willful or intentional breach of the terms and provisions of this Agreement by such Party prior to such termination or to limit or
impair the right of either such party to pursue all legal remedies with respect to fraud or any such willful or intentional breach.

(g) . Purchaser and Oramed hereby agree that in consideration of the promises and the
mutual covenants and agreements contained herein, notwithstanding anything to the contrary therein in any Subject Warrant (including Sections 2 or Section 6 of each Subject Warrant), Oramed shall be, and hereby is, entitled to receive all
dividends, distributions, equity, interest or subscription rights issuances made, issued or delivered to the holders of share capital of Purchaser as if Oramed holds the Warrant Shares which Oramed would be entitled to receive upon an exercise of
any Subject Warrants, so long as Oramed continues to hold such Subject Warrants at the time of the applicable record date (or